The Pathology Report
The Pathology Report
Podcast Description
The Royal College of Pathologists of Australasia (RCPA) is proud to present The Pathology Report – a podcast exploring the latest insights, innovations, and challenges in pathology.
In Season One, recorded live at Pathology Update 2025, we bring you conversations with leading experts in pathology and laboratory medicine. Each episode delves into key areas of the field, highlighting the pivotal role pathology plays in modern healthcare.
Stay tuned for the first episodes, landing soon in your favourite podcast feed.
Find out more at rcpa.edu.au.
Podcast Insights
Content Themes
The podcast focuses on key themes within pathology, including the integration of artificial intelligence in diagnostics, healthcare equity related to big data, and the evolving challenges in laboratory practices. Example episodes explore topics such as AI's impact on overdiagnosis, the balance between automation and clinician workload, and issues of data ownership and patient consent in clinical settings.
Welcome to The Pathology Report, the podcast that brings you the latest insights and innovations in pathology. Each episode features a conversation with a panel of local and international content matter experts, offering:
· perspectives on emerging developments in pathology – including both opportunities and limitations
· expert insight into the profession’s key challenges, and potential solutions
· thoughtful discussion that reflects the diversity of perspectives across the field.
Created by the Royal College of Pathologists of Australasia (RCPA), the Pathology Report offers a convenient continuing professional development (CPD) option for pathologists and other medical professionals.
Find out more at rcpa.me/the-pathology-report
Thank you to our partner Astellas for their support in producing this podcast episode.
Claudin-18.2 (CLDN18.2) represents an important emerging biomarker in gastrointestinal cancer.
In this episode of The Pathology Report, host Dr Donna Lenghaus is joined by Professor Beena Kumar and A/Professor Katrin Sjoquist to discuss the evolving role of biomarkers in the management of gastric carcinoma, and how CLDN18.2 testing can help identify patients who may benefit from targeted therapies.
Key topics discussed include:
- How improved understanding of tumour biology and identification of biomarkers is changing the management of gastrointestinal cancers.
- The clinical utility of using CLDN18.2 testing to facilitate targeted therapies for eligible patients, including Zolbetuximab.
- Pathology considerations, including appropriate biopsy, controls, specimen age, tumour location, scoring and reporting standards.
- The role of the multidisciplinary team.
- Resources and other emerging biomarkers.
In exploring the use of CLDN18.2 as a predicative biomarker, this episode highlights that accurate immunohistochemistry testing, adequate tissue, standardised reporting and strong communication between pathology and clinical teams is essential to ensuring eligible patients can access targeted treatments.
RCPA members
This podcast is an RCPA-endorsed CPD activity. Each episode gives you an opportunity to gain CPD hours in three easy steps:
Step 1. Listen or watch the podcast here, on your favourite podcast channel or on YouTube
Step 2. To claim your CPD hours, please complete and pass this short online quiz
Step 3. Sit back and let us load your CPD hours into your CPD profile for you.
Did you enjoy this episode? Make sure you subscribe to The Pathology Report so you know when the next episode drops, and consider leaving us a five-star review so more people can discover the podcast.
The Pathology Report is produced by the Royal College of Pathologists of Australasia and is part of the Talking HealthTech Podcast Network.
Learn more about the RCPA atrcpa.edu.au and discover other shows in the network attalkinghealthtech.com/podcast/network.
Disclaimer
This podcast’s information is provided for general reference and was obtained from publicly accessible sources. The Podcast Collaborative neither produces nor verifies the content, accuracy, or suitability of this podcast. Views and opinions belong solely to the podcast creators and guests.
For a complete disclaimer, please see our Full Disclaimer on the archive page. The Podcast Collaborative bears no responsibility for the podcast’s themes, language, or overall content. Listener discretion is advised. Read our Terms of Use and Privacy Policy for more details.